1 Cash-Producing Stock to Own for Decades and 2 That Underwhelm [Yahoo! Finance]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Luckily for you, we built StockStory to help you separate the good from the bad. Keeping that in mind, here is one cash-producing company that reinvests wisely to drive long-term success and two that may face some trouble. Two Stocks to Sell: DocuSign (DOCU) Trailing 12-Month Free Cash Flow Margin: 32.9% Creating the digital equivalent of "sign on the dotted line" for over a billion users worldwide, DocuSign (NASDAQ:DOCU) provides an agreement management platform that enables businesses to electronically prepare, sign, and manage documents and contracts. Why Are We Cautious About DOCU? Average ARR growth of 8.7% over the last year has disappointed, suggesting it's had a hard time winning long-term deals and renewals Estimated sales growth of 8.4% for the next 12 months is soft and implies weaker demand Operating profits increased over the last year as the company gained some leverage on its fixed costs and became more efficient At $46.92 per share, DocuSign trades a
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- Royalty Pharma and J&J partner to develop autoimmune treatment [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated DiseasesGlobeNewswire
- Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma Appoints Lucas Glass as Head of Artificial IntelligenceGlobeNewswire
- How The Royalty Pharma (RPRX) Story Is Shifting With New Deals And Updated Expectations [Yahoo! Finance]Yahoo! Finance
RPRX
Sec Filings
- 3/31/26 - Form 4
- 3/23/26 - Form 144
- 3/19/26 - Form 144
- RPRX's page on the SEC website